Chung-pu Wu
Taoyuan, TNQ 33302, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
BLU-945 suppresses ABCB1-mediated drug efflux and restores chemosensitivity in multidrug-resistant cancer cells.
Journal: European journal of pharmacology
Published: April 30, 2026
Attenuation of ABCG2-dependent drug efflux by befotertinib restores chemosensitivity in multidrug-resistant non-small cell lung cancer cells.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 24, 2026
Erratum to "The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs" [European Journal of Pharmaceutical Sciences (2025) 107337].
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: December 05, 2025
Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cells.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: November 12, 2025
Befotertinib restored chemosensitivity to multidrug-resistant cancer cells by inhibiting the drug efflux activity of ABCB1.
Journal: The Journal of pharmacy and pharmacology
Published: September 03, 2025
The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: August 29, 2025
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2.
Journal: European journal of pharmacology
Published: November 08, 2024
The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug efflux.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 01, 2024
Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 16, 2024
ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.
Journal: International journal of molecular sciences
Published: April 13, 2024
Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 02, 2023
Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2.
Journal: ACS pharmacology & translational science
Published: September 02, 2023
Last Updated: 09/26/2026